# First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC

> **NCT05745350** · PHASE2 · RECRUITING · sponsor: **Xiaorong Dong** · enrollment: 45 (estimated)

## Conditions studied

- Small Cell Lung Cancer Extensive Stage

## Interventions

- **DRUG:** Pembrolizumab, Plinabulin plus Etoposide and Platinum

## Key facts

- **NCT ID:** NCT05745350
- **Lead sponsor:** Xiaorong Dong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-07
- **Primary completion:** 2025-06
- **Final completion:** 2025-12
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05745350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05745350, "First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05745350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*